Julia Hardick

Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in <i>KRAS</i>-Mutant Pancreatic and Colorectal Cancer

Jörn Weisner, Ina Landel, Christoph Reintjes et al. · Cancer Research · 2019 · 88 citations

Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt

Niklas Uhlenbrock, Steven P. Smith, Jörn Weisner et al. · Chemical Science · 2019 · 65 citations · Full text

Molecular Biology, Chemical Biology, Pharmaceutical Chemistry +18

Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S

Jonas Lategahn, Marina Keul, Philip Klövekorn et al. · Chemical Science · 2019 · 48 citations · Full text

Targeting the MKK7–JNK (Mitogen-Activated Protein Kinase Kinase 7–c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors

Patrik Wolle, Julia Hardick, Shane J. F. Cronin et al. · Journal of Medicinal Chemistry · 2019 · 28 citations · Full text

Covalent Inhibitors, Drug Target, Effective Covalent Inhibitor +17

Covalent Lipid Pocket Ligands Targeting p38α MAPK Mutants

Mike Bührmann, Julia Hardick, Jörn Weisner et al. · Angewandte Chemie International Edition · 2017 · 18 citations